Hypoaldosteronism natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(21 intermediate revisions by 2 users not shown)
Line 5: Line 5:


==Overview==
==Overview==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
If left untreated, hypoaldosteronism leads to [[hyperkalemia]] which can alter the function of [[Electrical conduction system of the heart|cardiac conduction pathways]]. Depending upon the severity of hypoaldosteronism, [[hyperkalemia]] can be a life threatening condition. When [[serum potassium]] rises above ≥ 9 mEq/L, [[hyperkalemia]] may lead to [[ventricular fibrillation]], [[PEA]] and even [[cardiac arrest]]. Common [[complications]] of hypoaldosteronism include [[hyperkalemia]], [[metabolic acidosis]], [[hypotension]], [[hypovolemia]] and [[hyponatremia]]. Depending on the extent of the [[hyperkalemia]] and underlying [[renal]] or [[Adrenal gland|adrenal]] condition at the time of [[diagnosis]], the [[prognosis]] of [[hypoaldosteronism]] may vary. Prognosis of hypoaldosteronism is generally good for [[patients]] who receive treatment.


OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==


===Natural History===
===Natural History===
If left untreated, hypoaldosteronism can progress to hyperkalemia, hyponatremia with hypo or hyper volemia. Hyperkalemia is an acute life threatening condition since it can alter the electrical activity of the heart and lead to life threatening rhythms. Patients with severe hyperkalemia (>7.5 mmol/l) may present with [[Bundle branch block|bundle branch blocks]] or [[Fascicular block|fascicular blocks]]. When serum [[potassium]] level ≥ 9 mEq/L, hyperkalemia may lead to [[ventricular fibrillation]], [[PEA]] and even [[cardiac arrest]]. Hyponatremia is unusual in isolated hypoaldosteronism since cortisol leads to suppression of ADH. However, patients of adrenal insufficiency have decreased cortisol and aldosterone which may progress to hyponatremia. Depending upon the presence of underlying conditions such as kidney disease or heart condition patient may be hypervolemic. Otherwise, aldosterone deficiency leads to decreased sodium and water absorption which predisposes to hypovolemia.
*If left untreated, hypoaldosteronism can progress to [[hyperkalemia]] and [[hyponatremia]] with [[hypovolemia]] or [[hypervolemia, complications and prognosis|hypervolemia]].<ref name="pmid18053465">{{cite journal |vauthors=Sood MM, Sood AR, Richardson R |title=Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia |journal=Mayo Clin. Proc. |volume=82 |issue=12 |pages=1553–61 |year=2007 |pmid=18053465 |doi=10.1016/S0025-6196(11)61102-6 |url=}}</ref><ref name="pmid6268928">{{cite journal |vauthors=Sterns RH, Cox M, Feig PU, Singer I |title=Internal potassium balance and the control of the plasma potassium concentration |journal=Medicine (Baltimore) |volume=60 |issue=5 |pages=339–54 |year=1981 |pmid=6268928 |doi= |url=}}</ref><ref name="pmid15786818">{{cite journal |vauthors=Mann JF, Yi QL, Sleight P, Dagenais GR, Gerstein HC, Lonn EM, Bosch J |title=Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study |journal=Clin. Nephrol. |volume=63 |issue=3 |pages=181–7 |year=2005 |pmid=15786818 |doi= |url=}}</ref>
*[[Hyperkalemia]] is an acute life threatening condition since it can alter the [[Electrical conduction system of the heart|electrical activity of the heart]] and lead to life threatening [[arrhythmias]].  
*Patients with severe [[hyperkalemia]] (>7.5 mmol/l) may present with [[Bundle branch block|bundle branch blocks]] or [[Fascicular block|fascicular blocks]].  
*When serum [[potassium]] level ≥ 9 mEq/L, hyperkalemia may lead to [[ventricular fibrillation]], [[PEA]] and even [[cardiac arrest]].  
*[[Hyponatremia]] is unusual in isolated hypoaldosteronism since under normal conditions [[cortisol]] leads to suppression of [[ADH]]. However, patients of [[adrenal insufficiency]] have decreased [[cortisol]] and [[aldosterone]] which may progress to [[hyponatremia]].  
*[[Aldosterone]] deficiency leads to decreased [[sodium]] and [[water]] [[absorption]] which predisposes to [[hypovolemia]]. However, patients with underlying conditions such as [[kidney disease]] or [[heart condition]] may be [[Hypervolemia|hypervolemic]].


===Complications===
===Complications===
*Common complications of hypoaldosteronism include:
*Common [[complications]] of hypoaldosteronism include:<ref name="SousaCabral2016">{{cite journal|last1=Sousa|first1=André Gustavo P|last2=Cabral|first2=João Victor de Sousa|last3=El-Feghaly|first3=William Batah|last4=Sousa|first4=Luísa Silva de|last5=Nunes|first5=Adriana Bezerra|title=Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management|journal=World Journal of Diabetes|volume=7|issue=5|year=2016|pages=101|issn=1948-9358|doi=10.4239/wjd.v7.i5.101}}</ref>
**Hyperkalemia
**[[Hyperkalemia]]
**Hypotension  
**[[Hypotension]]
**Hypovolemia
**[[Hypovolemia]]
**Metabolic acidosis
**[[Metabolic acidosis]]
**Hyponatremia
**[[Hyponatremia]]


===Prognosis===
===Prognosis===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
*Depending on the extent of the [[hyperkalemia]] and underlying [[renal]] or [[adrenal]] condition at the time of [[diagnosis]], the [[prognosis]] of hypoaldosteronism may vary.<ref name="SousaCabral2016">{{cite journal|last1=Sousa|first1=André Gustavo P|last2=Cabral|first2=João Victor de Sousa|last3=El-Feghaly|first3=William Batah|last4=Sousa|first4=Luísa Silva de|last5=Nunes|first5=Adriana Bezerra|title=Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management|journal=World Journal of Diabetes|volume=7|issue=5|year=2016|pages=101|issn=1948-9358|doi=10.4239/wjd.v7.i5.101}}</ref><ref name="pmid12133029">{{cite journal |vauthors=Ahmed A |title=Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? |journal=J Am Geriatr Soc |volume=50 |issue=7 |pages=1297–300 |year=2002 |pmid=12133029 |doi= |url=}}</ref><ref name="pmid15017529">{{cite journal |vauthors=Mangrum AJ, Bakris GL |title=Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues |journal=Semin. Nephrol. |volume=24 |issue=2 |pages=168–75 |year=2004 |pmid=15017529 |doi= |url=}}</ref>
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
 
*The presence of hyperkalemia is associated with cardiac arrhythmias which can be fatal.
*[[Prognosis]] is generally good for patients of hypoaldosteronism who receive treatment.
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*Untreated [[patients]] risk having [[hyperkalemia]] which is associated with [[cardiac arrhythmias]] that can be [[fatal]].
*Patient having underlying [[renal insufficiency]] or [[diabetic nephropathy]] generally progresses to [[End stage renal disease|end stage stage renal disease]]. Drugs such as [[ACE inhibitor]] and [[angiotensin receptor blockers]] which are the mainstay of treatment with [[diabetes]] and [[renal dysfunction]] are avoided in hypoaldosteronism since these may lead to [[hyperkalemia]].


==References==
==References==
Line 38: Line 37:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Endocrinology]]
[[Category:Nephrology]]
[[Category:Emergency medicine]]
[[Category:Medicine]]
[[Category:Up-To-Date]]

Latest revision as of 16:39, 18 October 2017

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism natural history, complications and prognosis

CDC on Hypoaldosteronism natural history, complications and prognosis

Hypoaldosteronism natural history, complications and prognosis in the news

Blogs on Hypoaldosteronism natural history, complications and prognosis

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

If left untreated, hypoaldosteronism leads to hyperkalemia which can alter the function of cardiac conduction pathways. Depending upon the severity of hypoaldosteronism, hyperkalemia can be a life threatening condition. When serum potassium rises above ≥ 9 mEq/L, hyperkalemia may lead to ventricular fibrillation, PEA and even cardiac arrest. Common complications of hypoaldosteronism include hyperkalemia, metabolic acidosis, hypotension, hypovolemia and hyponatremia. Depending on the extent of the hyperkalemia and underlying renal or adrenal condition at the time of diagnosis, the prognosis of hypoaldosteronism may vary. Prognosis of hypoaldosteronism is generally good for patients who receive treatment.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

References

  1. Sood MM, Sood AR, Richardson R (2007). "Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia". Mayo Clin. Proc. 82 (12): 1553–61. doi:10.1016/S0025-6196(11)61102-6. PMID 18053465.
  2. Sterns RH, Cox M, Feig PU, Singer I (1981). "Internal potassium balance and the control of the plasma potassium concentration". Medicine (Baltimore). 60 (5): 339–54. PMID 6268928.
  3. Mann JF, Yi QL, Sleight P, Dagenais GR, Gerstein HC, Lonn EM, Bosch J (2005). "Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study". Clin. Nephrol. 63 (3): 181–7. PMID 15786818.
  4. 4.0 4.1 Sousa, André Gustavo P; Cabral, João Victor de Sousa; El-Feghaly, William Batah; Sousa, Luísa Silva de; Nunes, Adriana Bezerra (2016). "Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management". World Journal of Diabetes. 7 (5): 101. doi:10.4239/wjd.v7.i5.101. ISSN 1948-9358.
  5. Ahmed A (2002). "Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?". J Am Geriatr Soc. 50 (7): 1297–300. PMID 12133029.
  6. Mangrum AJ, Bakris GL (2004). "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues". Semin. Nephrol. 24 (2): 168–75. PMID 15017529.

Template:WH Template:WS